$0.45
(Market cap
$1,354 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
31.2
Div. Yield
0 %
Quality Score
/10
Growth Score
/10
Valuation Score
/10
Momentum Score
/10
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-1.4 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-4.8
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$-1
-
Face value
--
-
Shares outstanding
92,478,154
5 Years Aggregate
CFO
$-67.81 Mln
EBITDA
$-94.70 Mln
Net Profit
$-107.54 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Alpha Tau Medical (DRTS)
| 204.4 | 26.4 | 42.4 | 326.9 | 61.3 | 8.8 | -- |
|
BSE Sensex
| -9.6 | -2.7 | 2.9 | -5.0 | 5.4 | 5.7 | 10.4 |
|
Company
|
2025
|
2023
|
|---|---|---|
|
Alpha Tau Medical (DRTS)
| 59.7 | -5.3 |
|
BSE Sensex
| 9.1 | 18.7 |
|
BSE Sensex
| 9.1 | 18.7 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Shareholding Pattern
View DetailsAbout Alpha Tau Medical (DRTS)
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer. Its Alpha-DaRT... technology is in clinical trials for various forms comprising skin, oral, pancreatic, prostate, lung, liver, and breast cancers; and preclinical clinical studies for mouse tumors and human-derived tumors. The company has a strategic collaboration agreement to develop and commercialize Alpha DaRT for the treatment of prostate cancer. The company is headquartered in Jerusalem, Israel. Read more
-
CEO & Chairman
Mr. Uzi Sofer
-
CEO & Chairman
Mr. Uzi Sofer
-
Headquarters
Jerusalem
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Alpha Tau Medical (DRTS)
What is the current share price of Alpha Tau Medical Ltd (DRTS) Today?
The share price of Alpha Tau Medical Ltd (DRTS) is $15.07 (NASDAQ) as of 04-Sep-2026 13:38 EDT. Alpha Tau Medical Ltd (DRTS) has given a return of 61.31% in the last 3 years.
What is the current PB & PE ratio of Alpha Tau Medical Ltd (DRTS)?
Since, TTM earnings of Alpha Tau Medical Ltd (DRTS) is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
-9.95 |
5.50 |
2024 |
-6.84 |
3.47 |
2023 |
-7.19 |
2.48 |
2022 |
-6.51 |
2.08 |
2021 |
-17.11 |
-13.41 |
What is the 52 Week High and Low of Alpha Tau Medical Ltd (DRTS)?
The 52-week high and low of Alpha Tau Medical Ltd (DRTS) are Rs 15.17 and Rs 3.43 as of 05-Sep-2026.
What is the market cap of Alpha Tau Medical Ltd (DRTS)?
Alpha Tau Medical Ltd (DRTS) has a market capitalisation of $ 1,354 Mln as on 28-Aug-2026. As per SEBI classification, it is a company.
Should I invest in Alpha Tau Medical Ltd (DRTS)?
Before investing in Alpha Tau Medical Ltd (DRTS), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.